J&J Submits Novel Protease Inhibitor For Treatment Of HIV
This article was originally published in The Pink Sheet Daily
Approval of TMC-114 would mark J&J’s entry into the HIV treatment category.
You may also be interested in...
The firm’s acute migraine treatment Nurtec ODT generated $65m in 2020 after launching a year ago. Biohaven aims for Nurtec to become the leader in what could be a $4bn-$5bn category in the US.
Merck & Co. reached a deal to acquire the developer of targeted immune modulators for $1.85bn. Pandion CEO Kakkar talked to Scrip about the acquisition.
Big pharma business development executives forecast a competitive and active deal-making year ahead for the industry at the Biocom partnering conference.